Optimized Stent Performance
COBRA PzF NanoCoated Coronary Stent (NCS)
A New Category of Stent
COBRA PzF NCS is the world’s first non-drug eluting, nanocoated stent that allows physicians to safely and effectively treat their patients who may benefit from a short, minimum 1-month DAPT requirement.5
Designed with
Healing in Mind
The revolutionary COBRA PzF NCS is a new nanocoated, non drug-eluting stent that allows physicians to safely and effectively treat their patients who may benefit from a short, minimum 1-month DAPT requirement.1
Designed with Healing in Mind
The revolutionary COBRA PzF NCS is a new nanocoated, non drug-eluting stent that allows physicians to safely and effectively treat their patients who may benefit from a short, minimum 1-month DAPT requirement.1
Exceptional Safety & Efficacy
In the eCOBRA all-comers study, COBRA PzF NCS demonstrated an excellent safety profile with low TLR in patients at high risk of bleeding and stent thrombosis in a real-world setting.2
“The study demonstrated good follow-up with excellent numbers…One of the numbers I was most impressed with was the need for repeat revascularization…given that its [COBRA’s] major feature is thromboresistance, 4% TLR is really quite spectacularly good.”
-Dr. Philip Urban, MD, Medical Co-Director CERC, Paris, France
Click here to watch the complete interview.
At 270 Days
0.4%
Late Stent Thrombosis2 (Definite/Probable)
4.3%
TLR‡2
~30% OAC
21% STEMI
56% ACS
High Risk Patients2
N: 940 | France Multicenter | Mean Age: 73
COBRA PzF NCS indications include patients with diabetes mellitus
Polyzene-F NanoCoating
Makes the Difference
Polyzene-F is a nano-thin surface coating that has been studied extensively in the past 20+ years, demonstrating thrombo-resistant, anti-inflammatory and rapid healing effects in preclinical studies.3-7*
Polyzene-F NanoCoating Makes the Difference
Polyzene-F is a nano-thin surface coating that has been studied extensively in the past 20+ years, demonstrating thrombo-resistant, anti-inflammatory and rapid healing effects in preclinical studies.3-7*
Delivery System Specifications
Product Ordering Information
The COBRA PzF coronary stent is FDA and CE approved and commercially available for purchase. Contact a CeloNova sales representative today.
* AS DEMONSTRATED IN HUMAN AND PRECLINICAL STUDIES.
Correlation between bench testing, animal studies and humans have not been determined.
‡ Stent thrombosis defined as ARC Definite, Probable and Possible; stent thrombosis and cTLR assessed at 270 days [95% Confidence Interval ST, 0.00%, 1.29%, cTLR, 2.45%, 7.67%]
+ For more information about the COBRA REDUCE IDE trial, please visit: clinicaltrials.gov/ct2/show/NCT02594501.
Correlation between bench testing, animal studies and humans have not been determined.
‡ Stent thrombosis defined as ARC Definite, Probable and Possible; stent thrombosis and cTLR assessed at 270 days [95% Confidence Interval ST, 0.00%, 1.29%, cTLR, 2.45%, 7.67%]
+ For more information about the COBRA REDUCE IDE trial, please visit: clinicaltrials.gov/ct2/show/NCT02594501.
- Levine G, Bates E, Bittl J, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients with Coronary Artery Disease. Circulation. 2016;134(10):e123-55.
- Maillard, L, de Labriolle, A, Brasselet, C, et al. Evaluation of the safety and efficacy of the Cobra PzF NanoCoated coronary stent in routine, consecutive, prospective, and high‐risk patients: The e‐Cobra study. Catheter Cardiovasc Interv. 2020; 1– 10. https://doi.org/10.1002/ccd.29065
- Koppara T, Sakakura K, Pacheco E, et al. Preclinical evaluation of a novel polyphosphazene surface modified stent. International Journal of Cardiology. 2016; 222:217-225.
- Mrowietz C, Franke R, Seyfert U, et al. Haemocompatibility of polymer-coated stainless steel stents as compared to uncoated stents. Clinical Hemorheology and Microcirculation. 2005; 32:89–103.
- Richter G, Stampfl U, Stampfl S, et al. A New Polymer Concept for Coating of Vascular Stents Using PTFEP (poly(bis(trifluoroethoxy)phosphazene) to Reduce Thrombogenicity and Late In-Stent Stenosis. Investigative Radiology. 2005; 40(4):210-218.
- Radeleff B, Thierjung H, Stampfl U, et al. Restenosis of the CYPER-Select, TAXUS-Express, and Polyzene-F NanoCoated Cobalt-Chromium Stents in the Minipig Coronary Artery Model. Cardiovasc Intervent Radiol. 2007.
- Tamburino C, Giacoppo D, Capodanno D, et al. The Rapid Evaluation of Vessel Healing after Angioplasty (REVEAL) trial. Interv.Cardiol. 2011; 3 (4): 451-460.